Peptide Profile
Retatrutide
LY3437943
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, combining the complementary metabolic…
- Half-life
- ~6 days
- Routes
- subcutaneous
Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.
Educational research tools — not medical advice.
What Retatrutide is
About Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist; targets three pathways for synergistic fat reduction
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, combining the complementary metabolic actions of all three incretin and counterregulatory hormone pathways in a single weekly injection. The GLP-1 component drives satiety and insulin secretion, GIP enhances adipose lipid metabolism and further modulates appetite, and glucagon receptor activation increases energy expenditure — together producing greater weight loss than single or dual agonists in the same receptor class. A Phase 2 randomized controlled trial published in the New England Journal of Medicine demonstrated dose-dependent weight reductions of up to 24% of body weight at 48 weeks, among the largest reported for any pharmacological obesity treatment. Retatrutide has not received FDA approval; it is under Phase 3 registrational evaluation (TRIUMPH trials) as of 2025 for obesity, obstructive sleep apnea, and knee osteoarthritis. Retatrutide cost and access As of mid-2026, retatrutide has not received FDA approval and is not commercially available as a branded pharmaceutical. It is in late-stage (Phase 3) clinical development through Eli Lilly. Access pathways include: enrollment in active clinical trials (listed on ClinicalTrials.gov), research-use peptide vendors who supply retatrutide for laboratory/research contexts (not for human use), and a limited number of compounding pharmacies that compound investigational or pre-approval compounds under provider-supervised protocols. Cost per month of research-grade retatrutide from vendors varies considerably by quantity and formulation. Branded pharmaceutical pricing will be established at approval; given tirzepatide's pricing trajectory and the triple-agonist mechanism, analyst forecasts suggest a premium pricing position relative to existing GLP-1 agonists. Retatrutide vs survodutide: Survodutide (BI 456906, Boehringer Ingelheim + Zealand Pharma) is a dual GLP-1 and glucagon receptor agonist in Phase 3 development for MASH (metabolic dysfunction-associated steatohepatitis) and obesity. Compared to retatrutide, survodutide lacks the GIP receptor component; retatrutide's triple agonism adds GIP-mediated adipose lipid oxidation to the GLP-1 + glucagon combination. In trial comparisons, both compounds show substantial weight reductions (retatrutide 24.2% at 12mg/week in Phase 2; survodutide 18.7% at highest dose in Phase 2). Neither compound has a direct head-to-head trial yet. Both represent the next tier beyond tirzepatide in the GLP-1 + additional agonism category. Retatrutide's MASH indication (liver fat reduction) also overlaps with survodutide's primary development focus. The competitive landscape in this category is evolving rapidly as multiple Phase 3 readouts are expected through 2026–2027.
Retatrutide Benefits & Research Areas
Research Signals
Commonly researched in the context of
Population research notes
These signals reflect research interest areas, not treatment indications.
Retatrutide half-life calculator
Compound & timing
Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.
What the evidence says about Retatrutide
Research Evidence
based on 13 studies · 1 RCT · most recent 2026
Regulatory Status
- Availability Status
- Research Only
- FDA Status
- Investigational
- Source
- View FDA source →
Triple GIP/GLP-1/glucagon agonist by Eli Lilly. Phase 3 TRIUMPH trials for obesity and T2D (NCT05929066). Phase 2 data published NEJM 2023. NDA submission expected 2026-2027.
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
13 sources cited · 1 strong · 12 moderate
1 RCT · 3 Cohorts · 9 Reviews
Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial
New England Journal of Medicine · 2023
In a 48-week phase 2 trial, the triple GIP/GLP-1/glucagon receptor agonist retatrutide 12 mg reduced mean body weight by 24.2% compared with 2.1% for placebo in adults with obesity, with participants achieving weight reductions at the high end of any pharmacological agent studied to date.
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review.
Eur J Clin Pharmacol · 2026
# Summary Research found that dysesthesia (abnormal skin sensations) is associated with GLP-1 receptor agonist therapies, with different agents showing distinct patterns—exenatide linked to reduced sensation, while semaglutide and tirzepatide associated with increased sensation and burning—with symptoms appearing dose-dependent and often resolving upon discontinuation. This study demonstrated that pharmacovigilance data strengthens evidence for dysesthesias previously observed in clinical trials of semaglutide, tirzepatide, and retatrutide.
Beyond weight loss: multisystem benefits of obesity medications.
Lancet Diabetes Endocrinol · 2026
A review of RCT and meta-analysis evidence on emerging multiagonist obesity medications including retatrutide found beneficial multisystem effects beyond weight loss, encompassing metabolic, cardiovascular, neuropsychiatric, and quality-of-life outcomes, reflecting a combination of weight-mediated and direct receptor-mediated mechanisms.
Show 10 more sources ↓
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
BMJ · 2026
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High Blood Press Cardiovasc Prev · 2026
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists.
Diabetes Metab Syndr Obes · 2026
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ann Intern Med · 2026
Retatrutide: Triple acting jab for type 2 diabetes lowers blood sugar and boosts weight loss, trial reports.
BMJ · 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.
Medicina (Kaunas) · 2026
# Summary Research found that retatrutide, a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways, demonstrates early clinical promise as a potential therapeutic approach for metabolic dysfunction-associated steatotic liver disease through hepatoprotective effects and metabolic improvement. This study highlighted that incretin-based therapies may address the underlying metabolic dysfunction driving liver disease progression, though evidence regarding effects on fibrosis advancement remains limited.
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes.
J Clin Endocrinol Metab · 2026
# Summary Research found that retatrutide treatment was associated with changes in metabolites related to fatty acid oxidation and insulin resistance markers, with these metabolic changes appearing to mediate a substantial portion of the observed weight reduction in participants with obesity. This study demonstrated that these favorable metabolic shifts occurred in both individuals with and without type 2 diabetes, suggesting retatrutide may produce benefits beyond weight loss through alterations in underlying metabolic pathways.
Diabetes Mellitus and Stroke: Pathophysiological Connections and Therapeutic Potential of GLP-1 and GLP-1/GIP Receptor Agonists.
Pharmaceutics · 2026
# Summary Research found that GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, including emerging agents like retatrutide, demonstrate potential therapeutic benefits in reducing stroke risk and improving outcomes in patients with diabetes mellitus. This study demonstrated that while current evidence supports these therapies' role in stroke prevention through cardiovascular benefits, larger long-term clinical trials are needed to fully establish their efficacy and define their place in post-stroke management and cerebrovascular risk reduction strategies.
Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ann Intern Med · 2026
Design of the TRIUMPH phase 3 clinical trial programme for retatrutide in obesity and cardiometabolic disease
Diabetes, Obesity and Metabolism · 2025
This paper describes the design of the TRIUMPH phase 3 trial program evaluating retatrutide across more than 5,800 participants with obesity and cardiometabolic disease, including cardiovascular outcomes, kidney disease, and metabolic dysfunction-associated steatohepatitis endpoints, providing context for the confirmatory evidence base being established.
Retatrutide Side Effects & Safety Considerations
No FDA-approved label for this compound. Cautions below are extrapolated from its mechanism/drug class — investigational; educational only.
Absolute contraindications
Warnings & cautions
Class-based (investigational)
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Third-party testing data
39 verified COAsMedian tested purity
99.7%
Median tested purity of 99.7% across 39 verified third-party lab COAs (interquartile range 99.5%–99.8%), as reported by the independent testing lab below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.
- Independent lab
- Janoshik Analytical
- Most recent test
- July 2026
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
Certificates of Analysis
- Vendor-publishedBlank Peptides
Retatrutide · Jul 8, 2026
- VerifiedJanoshik Analytical
Retatrutide · Jul 2, 2026 · View source COA
99.5%
Purity
- Vendor-publishedPeptide Partners
Retatrutide · Jul 2, 2026 · View source COA
99.8%
Purity
- Vendor-publishedVirtus Peptides
GLP-3 (RT) - - 10mg · Jul 1, 2026
99.6%
Purity
- Vendor-publishedVirtus Peptides
GLP-3 (RT) - - 30mg · Jul 1, 2026
99.8%
Purity
- Vendor-publishedNextGen Peptides
GLP-3 - 30mg · Lot RT30-6174 · Jun 25, 2026
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 23, 2026 · View source COA
99.5%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 19, 2026 · View source COA
99.3%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 17, 2026 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 17, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 16, 2026 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 16, 2026 · View source COA
99.7%
Purity
- VerifiedPrime Peptides
Retatrutide · Jun 15, 2026 · View source COA
99.5%
Purity
- Vendor-publishedNationwide Peptides
GLP-3R 5mg · Lot C221H342N46O68 · Jun 13, 2026 · View source COA
99.7%
Purity
- Vendor-publishedPeptide Partners
Retatrutide · Jun 12, 2026 · View source COA
99.4%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 12, 2026 · View source COA
99.8%
Purity
- Vendor-publishedPeptide Partners
Retatrutide · Jun 9, 2026 · View source COA
99.8%
Purity
- Vendor-publishedNextGen Peptides
Retatrutide - 10mg · Lot RT10-17 · Jun 9, 2026
99.1%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 5, 2026 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 5, 2026 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 5, 2026 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 3, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jun 2, 2026 · View source COA
99.6%
Purity
- Vendor-publishedNextGen Peptides
GLP-3 - 50mg · Lot RT50-01 · Jun 1, 2026
99.9%
Purity
- VerifiedPrime Peptides
Retatrutide · May 26, 2026 · View source COA
99.8%
Purity
- VerifiedPrime Peptides
Retatrutide · May 26, 2026 · View source COA
99.1%
Purity
- VerifiedJanoshik Analytical
Retatrutide · May 25, 2026 · View source COA
99.7%
Purity
- VerifiedJanoshik Analytical
Retatrutide · May 25, 2026 · View source COA
99.0%
Purity
- Vendor-publishedBlank Peptides
Retatrutide · Lot B-4755764-E · May 19, 2026
- VerifiedJanoshik Analytical
Retatrutide · May 18, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · May 18, 2026 · View source COA
99.7%
Purity
- VerifiedJanoshik Analytical
Retatrutide · May 7, 2026 · View source COA
100.0%
Purity
- VerifiedJanoshik Analytical
Retatrutide · May 7, 2026 · View source COA
99.5%
Purity
- VerifiedChameleon Peptides
Retatrutide · May 6, 2026 · View source COA
99.9%
Purity
- Vendor-publishedPurity Peptides
Retatrutide · Lot 260420RT103 · Apr 30, 2026
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 17, 2026 · View source COA
99.8%
Purity
- Vendor-publishedNextGen Peptides
GLP-3 - 10mg · Lot RT10-0429 · Apr 16, 2026
99.3%
Purity
- Vendor-publishedNextGen Peptides
GLP-3 - 20mg · Lot RT20-3618 · Apr 16, 2026
99.8%
Purity
- Vendor-publishedNextGen Peptides
GLP-3 - 30mg · Lot RT30-6173 · Apr 16, 2026
100.0%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.2%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 14, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 10, 2026 · View source COA
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Mar 25, 2026 · View source COA
99.6%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Mar 17, 2026 · View source COA
99.5%
Purity
- Vendor-publishedPurity Peptides
Retatrutide · Lot 260205RT203 · Feb 11, 2026
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jan 28, 2026 · View source COA
99.7%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jan 22, 2026 · View source COA
99.6%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jan 22, 2026 · View source COA
99.8%
Purity
- VerifiedChameleon Peptides
Retatrutide · Jan 13, 2026 · View source COA
99.4%
Purity
- VerifiedLimitless Peptides
Retatrutide · Nov 21, 2025 · View source COA
99.7%
Purity
- VerifiedLimitless Peptides
Retatrutide · Nov 21, 2025 · View source COA
99.7%
Purity
- VerifiedLimitless Peptides
Retatrutide · Oct 27, 2025 · View source COA
99.5%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Oct 9, 2025 · View source COA
99.7%
Purity
- Vendor-publishedPivot Labs Global
Retatrutide · Lot FP25-1022 · Oct 1, 2025
99.8%
Purity
- Vendor-publishedPivot Labs Global
Retatrutide · Lot FP25-1024 · Oct 1, 2025
99.8%
Purity
- Vendor-publishedPivot Labs Global
Retatrutide · Lot FP25-1026 · Oct 1, 2025
99.8%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jul 19, 2025 · View source COA
99.7%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Jul 19, 2025 · View source COA
99.7%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Apr 18, 2025 · View source COA
99.9%
Purity
- VerifiedJanoshik Analytical
Retatrutide · Feb 4, 2025 · View source COA
99.5%
Purity
PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Verified results come from an independent third-party lab database lookup. Vendor-published results are reported by the vendor itself and have not been independently verified by PeptideBase or a third-party lab.
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.
What people report about Retatrutide
Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.
Outcome distribution
- Improved
- 173 · 67%
- Mixed
- 46 · 18%
- No clear effect
- 29 · 11%
- Worse
- 10 · 4%
Outcomes by goal · improved % · reports
Side effects people mention
Counts are mentions across reports, not incidence rates.
Most reported
- Substantial, often dramatic fat loss was the most widely reported outcome across users.97×thread 1thread 2thread 3
- Appetite and food noise reduction were described as near-immediate and transformative.61×thread 1thread 2thread 3
- Cravings for alcohol, sweets, and addictive behaviors diminished markedly for many users.24×thread 1thread 2thread 3
- Some users experienced reduced libido, emotional blunting, or relationship disconnection while using the compound.18×thread 1thread 2thread 3
- Digestive disturbances including constipation and loose stools were among the most common physical side effects.19×thread 1thread 2thread 3
What they wish they'd known
- Alcohol tolerance drops significantly, with even small amounts producing stronger than expected effects.12×thread 1thread 2thread 3
- Sleep disruption and elevated heart rate were side effects many users did not anticipate.16×thread 1thread 2thread 3
- Scale weight alone can be misleading, as body composition changes often outpace what the scale shows.11×thread 1thread 2thread 3
- Emotional and libido-related changes caught many users off guard and affected their personal relationships.14×thread 1thread 2thread 3
Based on 258 community reports · Updated
Frequently Asked Questions — Retatrutide
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors, combining the complementary metabolic actions of all three incretin and counterregulatory hormone pathways in a single weekly injection. The GLP-1 component drives satiety and insulin secretion, GIP enhances adipose lipid metabolism and further modulates appetite, and glucagon receptor activation increases energy expenditure — together producing greater weight loss than single or dual agonists in the same receptor class.
profound weight loss, appetite suppression, metabolic improvement.
Research on Retatrutide primarily documents effects related to profound weight loss and appetite suppression and metabolic improvement. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Retatrutide include Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), Known hypersensitivity to the drug or excipients. 7 additional considerations are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
For Retatrutide, its FDA status is investigational (not FDA-approved), and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
85 providers in the directory currently offer Retatrutide.
Across 22 research vendors tracked on PeptideBase, Retatrutide has a median price of about $9.45 per mg, typically ranging $6.35–$14.53 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.
In a 48-week phase 2 trial, the triple GIP/GLP-1/glucagon receptor agonist retatrutide 12 mg reduced mean body weight by 24.2% compared with 2.1% for placebo in adults with obesity, with participants achieving weight reductions at the high end of any pharmacological agent studied to date.
How to get Retatrutide
Market Pricing
22 vendorsPrice per mg varies by quantity, vendor type, and formulation. Research use only.
Data verified July 2026 · Retatrutide price intelligence
Where to buy Retatrutide
85 providersClinics
10 providersAvendano Health Medical Wellness & Lab
Boca Raton, United StatesView →Carvalho Healthcare
Barnstable, United StatesView →Central Wisconsin Weight Loss and Wellness
Weston, United StatesView →Hawaii Wellness Clinic
Kailua-Kona, United StatesView →Javan Anti-Aging and Wellness Institute
Arlington, United StatesView →Medical Health Institute
Palmetto Bay, United StatesView →Nulevel Wellness Medspa
Gilbert, United StatesView →Peptides
Scottsdale, United StatesView →Protocol Health
Scarsdale, United StatesView →Revive Aesthetic Medicine & Wellness
St. George, United StatesView →
Questions to ask your provider
Stay updated on verified Retatrutide providers
New verified providers added weekly — delivered to your inbox.
Last updated
Keep exploring
Tools & Guides
Retatrutide Dose Calculator
Calculate exact draw volume and doses per vial for Retatrutide.
How to Reconstitute Peptides
Step-by-step guide: BAC water, vial prep, and storage after mixing.
Peptide Dosage Guide
Key factors that determine dosing in clinical practice.
Peptide Storage Guide
How to store lyophilized and reconstituted peptides.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Retatrutide — Per-mg Price Benchmark. Retrieved July 22, 2026, from https://peptidebase.io/peptides/retatrutide